Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionRockefeller Capital Management L.P.
Latest Disclosed Ownership67,826 shares
Latest Disclosed Value $ 242,817
Rockefeller Capital Management L.P. reports 5.61% increase in ownership of 9IP1 / Rocket Pharmaceuticals, Inc.

On May 14, 2026 - Rockefeller Capital Management L.P. filed a 13F-HR form disclosing ownership of 67,826 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1) valued at $190,930 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 16, 2026 disclosing 64,222 shares of Rocket Pharmaceuticals, Inc.. This represents a change in shares of 5.61% during the quarter. The current value of the position is $165,495 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 67,826 3,604 5.61 243 7.56 0.0002
2026-03-16 2025-12-31 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 64,222 -42,760 -39.97 225 -35.34 0.0004
2026-02-14 2025-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 64,222 -42,760 225 0.0004
2025-11-14 2025-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 106,982 10,000 10.31 349 46.84 0.0007
2025-08-14 2025-06-30 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 96,982 6,580 7.28 238 -60.63 0.0005
2025-08-08 2025-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 96,982 6,580 238 0.0003
2025-05-14 2025-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 90,402 1,837 2.07 603 -45.91 0.0015
2025-02-13 2024-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 88,565 -19,347 -17.93 1,113 -44.15 0.0029
2024-11-14 2024-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 107,912 20,939 24.08 1,993 6.46 0.0054
2024-08-12 2024-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 86,973 1,511 1.77 1,873 -18.68 0.0053
2024-05-14 2024-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 85,462 -2 -0.00 2,302 -10.11 0.0067
2024-02-14 2023-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 85,464 -6,400 -6.97 2,561 36.08 0.0086
2023-11-14 2023-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 91,864 9,750 11.87 1,882 15.39 0.0073
2023-08-14 2023-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 82,114 14,000 20.55 1,632 163,000.00 0.0063
2023-05-16 2023-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 68,114 21,000 44.57 1 -99.89 0.0050
2023-03-06 2022-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 47,114 5,000 11.87 921 37.26 0.0046
2022-11-02 2022-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 42,114 3,074 7.87 671 24.95 0.0035
2022-08-12 2022-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 39,040 38 0.10 537 -13.11 0.0029
2022-05-13 2022-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 39,002 600 1.56 618 -26.25 0.0030
2022-02-14 2021-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 38,402 25,200 190.88 838 112.69 0.0039
2021-11-12 2021-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 13,202 13,202 394 0.0021
2021-08-10 2021-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 0 -2,330 -100.00 0 -100.00
2021-05-11 2021-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,330 0 0.00 103 -18.90 0.0007
2021-02-12 2020-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,330 2,330 127 0.0010
2020-11-13 2020-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 0 -4,743 -100.00 0 -100.00
2020-08-12 2020-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 4,743 0 0.00 99 50.00 0.0010
2020-05-12 2020-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 4,743 -1,538 -24.49 66 -53.85 0.0009
2020-02-07 2019-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 6,281 -80 -1.26 143 93.24 0.0018
2019-11-12 2019-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,361 -248 -3.75 74 -26.00 0.0010
2019-08-09 2019-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,609 0 0.00 100 -13.79 0.0014
2019-05-10 2019-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 6,609 500 8.18 116 27.47 0.0017
2019-02-12 2018-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 6,109 0 0.00 91 -39.33 0.0016
2018-11-02 2018-09-30 13F Rocket Pharmaceuticals Common 77313F106 6,109 6,109 150 0.0023
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.